ArticleJournal of clinical medicine2020
Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: a meta-analysis.The American journal of emergency medicine · 2021Pooled it
- QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.Pharmacoepidemiology and drug safety · 2021Pooled it
- Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants.Clinical and translational science · 2026Trial
- ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.The European respiratory journal · 2025Trial
- Correction to "Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing".Clinical pharmacology and therapeutics · 2025Article
- Article
- Emerging Evidence on Balneotherapy and Thermal Interventions in Post-COVID-19 Syndrome: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study.BMC cardiovascular disorders · 2024Article
- Prevalence, Outcomes, and Predictors of Prolonged Corrected QT Interval in Hydroxychloroquine-Naïve Hospitalized COVID-19 Patients.Cardiovascular toxicology · 2024Article
- Use of drugs for hypertension or heart failure and the risk of death in COVID-19: association with loop-diuretics.European journal of clinical pharmacology · 2024Article
- QTc Prolongation to Predict Mortality in Patients Admitted with COVID-19 Infection: An Observational Study.Current vascular pharmacology · 2024Observational
- Prolongation of the QTc Interval at Admission is Associated with Increased Mortality in Patients with SARS-COV-2 during Hospitalization.Arquivos brasileiros de cardiologia · 2023Observational
- The natural history of QTc interval and its clinical impact in coronavirus disease 2019 survivors after 1 year.Frontiers in cardiovascular medicine · 2023Article
- Electrocardiographic Features and Outcome: Correlations in 124 Hospitalized Patients With COVID-19 and Cardiovascular Events.Journal of cardiothoracic and vascular anesthesia · 2022Article
- Combined Effects of Age and Comorbidities on Electrocardiographic Parameters in a Large Non-Selected Population.Journal of clinical medicine · 2022Article
- Medium-Term Outcomes in COVID-19.Journal of clinical medicine · 2022Article
- QTc interval prolongation, inflammation, and mortality in patients with COVID-19.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2022Article
- Article
- Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes.Frontiers in cardiovascular medicine · 2022Review
- Interleukin-6 Elevation Is a Key Pathogenic Factor Underlying COVID-19-Associated Heart Rate-Corrected QT Interval Prolongation.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of a prolonged QT interval in SARS-Cov2 infection is not well known.
objectiveTo determine whether the presence of a prolonged QT on admission is an independent factor for mortality in SARS-Cov2 hospitalized patients.
methodsSingle-center cohort of 623 consecutive patients with positive polymerase-chain-reaction test (PCR) to SARS Cov2, recruited from 27 February to 7 April 2020. An electrocardiogram was taken on these patients within the first 48 h after diagnosis and before the administration of any medication with a known effect on QT interval. A prolonged QT interval was defined as a corrected QT (QTc) interval >480 milliseconds. Patients were followed up with until 10 May 2020.
resultsSixty-one patients (9.8%) had prolonged QTc and only 3.2% had a baseline QTc > 500 milliseconds. Patients with prolonged QTc were older, had more comorbidities, and higher levels of immune-inflammatory markers. There were no episodes of ventricular tachycardia or ventricular fibrillation during hospitalization. All-cause death was higher in patients with prolonged QTc (41.0% vs. 8.7%,
conclusionsAlmost 10% of patients with COVID-19 infection have a prolonged QTc interval on admission. A prolonged QTc was independently associated with a higher mortality even after adjustment for age, comorbidities, and treatment with hydroxychloroquine and azithromycin. An electrocardiogram should be included on admission to identify high-risk SARS-CoV-2 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.